Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7;69(5):e0146424.
doi: 10.1128/aac.01464-24. Epub 2025 Apr 14.

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

J Raaijmakers  1 , S Salillas  1   2 , R Aarnoutse  3 , E Svensson  3   4 , L Te Brake  3 , R Stemkens  3 , H Wertheim  1 , W Hoefsloot  5 , J van Ingen  1
Affiliations

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

J Raaijmakers et al. Antimicrob Agents Chemother. .

Abstract

Bedaquiline has been proposed as a second-line drug to treat pulmonary disease caused by Mycobacterium avium complex. Based on in vitro synergy and interactions, a logical regimen would combine bedaquiline and clofazimine as additions to an ethambutol-azithromycin backbone. Here, we evaluate the added benefit of bedaquiline in a regimen of azithromycin, ethambutol, and clofazimine. THP-1 cells infected with M. avium ATCC 700898 were seeded in a hollow-fiber model and exposed to a regimen of azithromycin, ethambutol, and clofazimine with or without bedaquiline for 3 weeks. Epithelial lining fluid pharmacokinetic profiles of azithromycin and ethambutol were simulated, while an average steady-state concentration was sought for clofazimine and bedaquiline. Pharmacokinetics and pharmacodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug regimen was 0.65 (95% CI 0.63-0.67) and for the 4-drug regimen 0.65 (95% CI 0.64-0.67). The intracellular kill rate was 0.48 (95% CI 0.46-0.50) for the 3-drug regimen and 0.48 (95% CI 0.46-0.50) for the 4-drug regimen. Macrolide-tolerant subpopulations were observed with both treatment regimens at day 21. Bedaquiline does not add killing activity to a clofazimine-ethambutol-azithromycin regimen and did not improve suppression of the emergence of macrolide resistance, which makes its role as a second-line agent doubtful.

Keywords: M. avium; PK/PD; bedaquiline; hollow-fiber system; nontuberculous mycobacteria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Hollow-fiber pharmacodynamic measurements (solid lines) and emergence of macrolide resistance (dashed lines) of the growth control, clofazimine-based therapy, and bedaquiline added therapy in the hollow-fiber experiment. I, intracellular Log10CFU/mL; E, extracellular Log10CFU/mL counts.
See this image and copyright information in PMC

References

    1. van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A, Daley CL. 2021. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med 15:1387–1401. doi:10.1080/17476348.2021.1987891 - DOI - PubMed
    1. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 56:2000535. doi:10.1183/13993003.00535-2020 - DOI - PMC - PubMed
    1. Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, Loddenkemper R. 2018. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest 153:888–921. doi:10.1016/j.chest.2018.01.024 - DOI - PubMed
    1. Fröberg G, Maurer FP, Chryssanthou E, Fernström L, Benmansour H, Boarbi S, Mengshoel AT, Keller PM, Viveiros M, Machado D, et al. . 2023. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution. Clin Microbiol Infect 29:758–764. doi:10.1016/j.cmi.2023.02.007 - DOI - PubMed
    1. van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, Hasegawa N, Griffith DE, Hoefsloot W, Huitt G, Jarand J, Jhun BW, Loebinger MR, Marras TK, Morimoto K, Polverino E, Ringshausen FC, Santin M, Thomson R, Wagner D, Wallace RJ, Winthrop KL, Yim J-J. 2021. Management of drug toxicity in Mycobacterium avium complex pulmonary disease: an expert panel survey. Clin Infect Dis 73:e256–e259. doi:10.1093/cid/ciaa1361 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources